Description
Vortioxetine exhibits neuromodulatory, antidepressant, anxiolytic, and cognition enhancing activities. Vortioxetine modulates serotonin levels in the brain by inhibiting the serotonin transporter (SERT) and 5-HT3A/7 receptors, acting as a partial agonist at the 5-HT1B receptor, and acting as a full agonist at the 5-HT1A receptor. Vortioxetine also shows some agonist activity at β1-adrenergic receptors, although this is likely not related to its beneficial activities. In addition to its mood-modulating action, this compound also improves memory performance and reduces 5-HT-depletion-induced memory deficits in object recognition and Y-maze spontaneous alternation tests.
References
du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2013 Aug 2. [Epub ahead of print]. PMID: 23916504.
Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul;73(7):953-9. PMID: 22901346.
Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. PMID: 21486038.
